35
Participants
Start Date
November 16, 2021
Primary Completion Date
June 23, 2023
Study Completion Date
November 5, 2024
Ramucirumab (CYRAMZA®)
"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
Tusamitamab ravtansine (SAR408701)
"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
Investigational Site Number : 0560003, Edegem
Investigational Site Number : 0560001, Leuven
Investigational Site Number : 7240004, Granada
Investigational Site Number : 7240001, Madrid
Investigational Site Number : 7920001, Istanbul
Investigational Site Number : 7920002, Istanbul
Investigational Site Number : 6430001, Arkhangelsk
Investigational Site Number : 6430003, Pushkin, Saint- Petersburg
Investigational Site Number : 0560002, Brussels
Investigational Site Number : 3920002, Kashiwa-shi
Investigational Site Number : 3920004, Matsuyama
Investigational Site Number : 3920001, Sapporo
Investigational Site Number : 3920003, Sunto-gun
Investigational Site Number : 4100002, Seoul
Investigational Site Number : 4100003, Seoul
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 4100004, Seoul
Investigational Site Number : 7240002, Barcelona
Investigational Site Number : 7240003, Barcelona
Investigational Site Number : 7920003, Ankara
Investigational Site Number : 7920004, Malatya
Lead Sponsor
Sanofi
INDUSTRY